Australia's most trusted
source of pharma news
Tuesday, 21 January 2025
Posted 17 April 2024 AM
ASX-listed Imugene is reducing its headcount by 50 per cent with the sale of its North Carolina cell therapy manufacturing facility to Kincell Bio for up to US$6 million [AUD$9.3 million].
As a result of the transfer, which includes an upfront payment plus milestone-driven payments over the next three years, Imugene will realise US$32 million [AUD$49.9 million] in staff cost reductions, manufacturing efficiencies and overhead savings over the period.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.